# Vasoactive and Inotropic Agents: A Receptor-Based Approach

## Adrenergic Receptor Pharmacology Review

### Alpha-1 Receptors

Alpha-1 receptors are located on vascular smooth muscle. Their activation produces vasoconstriction, increasing systemic vascular resistance. They are the primary target for raising blood pressure through increased afterload.

### Beta-1 Receptors

Beta-1 receptors are found on the myocardium and the SA and AV nodes. Activation increases inotropy (contractility), chronotropy (heart rate), dromotropy (conduction velocity), and lusitropy (relaxation rate). While beta-1 stimulation augments cardiac output, it simultaneously increases myocardial oxygen demand.

### Beta-2 Receptors

Beta-2 receptors reside on bronchial smooth muscle and vascular smooth muscle, particularly in skeletal muscle beds. Activation causes bronchodilation and vasodilation. Beta-2 stimulation contributes to tachycardia and may reduce SVR.

### Vasopressin (V1) Receptors

V1 receptors are located on vascular smooth muscle and mediate vasoconstriction through a pathway entirely independent of the adrenergic system. This independence makes vasopressin effective in catecholamine-resistant vasodilatory shock, where adrenergic receptors may be desensitized.

### Dopaminergic (D1) Receptors

D1 receptors are found in the renal, mesenteric, coronary, and cerebral vasculature. Their activation causes local vasodilation. The concept of "renal dose" dopamine to selectively improve renal perfusion is no longer recommended, as clinical evidence does not support a protective benefit.

<image>Comprehensive pharmacology diagram showing the major adrenergic and non-adrenergic receptor subtypes (alpha-1, alpha-2, beta-1, beta-2, V1, D1) with their tissue locations, intracellular signaling pathways (Gq, Gs, Gi), and the physiologic effects of activation. Each receptor is color-coded and connected to the vasopressors/inotropes that act on it.</image>

## Phenylephrine

### Mechanism

Phenylephrine is a pure alpha-1 agonist with no direct beta activity.

### Hemodynamic Effects

Phenylephrine increases SVR and MAP. The resulting baroreceptor activation produces reflex bradycardia. In patients with a fixed stroke volume, such as those with severe aortic stenosis or HFrEF, the afterload increase may actually decrease cardiac output. It effectively increases coronary perfusion pressure.

### Clinical Use

Phenylephrine is the first-line agent for mild to moderate hypotension under spinal or epidural anesthesia. It is given as IV boluses of 50-200 mcg or as an infusion at 0.1-0.5 mcg/kg/min. It should be avoided in patients with significant LV dysfunction because the afterload increase without concomitant inotropy worsens cardiac output.

## Norepinephrine (Levophed)

### Mechanism

Norepinephrine is a potent alpha-1 agonist with moderate beta-1 activity and minimal beta-2 effect.

### Hemodynamic Effects

Norepinephrine increases SVR, MAP, and coronary perfusion pressure while providing a modest increase in contractility through its beta-1 activity. Its effect on heart rate is typically minimal because the chronotropic beta-1 stimulation is offset by baroreceptor-mediated reflex bradycardia.

### Clinical Use

Norepinephrine is the first-line vasopressor in septic shock according to the Surviving Sepsis Campaign guidelines, and it is also first-line for vasodilatory shock from other causes including post-CPB vasoplegia, anaphylaxis (as an adjunct), and neurogenic shock. It is administered as an infusion at 0.02-0.5 mcg/kg/min, titrated to a MAP target. The SOAP II trial demonstrated that norepinephrine is preferred over dopamine in most shock states, as dopamine was associated with significantly more arrhythmias. Norepinephrine is also increasingly used in obstetric anesthesia for managing spinal hypotension during cesarean delivery.

## Epinephrine

### Mechanism

Epinephrine acts on alpha-1, beta-1, and beta-2 receptors with a dose-dependent receptor profile. At low doses (below 0.05 mcg/kg/min), beta effects predominate, while higher doses progressively recruit alpha-mediated vasoconstriction.

### Hemodynamic Effects

Epinephrine increases heart rate, contractility, SVR (at higher doses), and cardiac output. Beta-2 activation produces bronchodilation. It significantly increases myocardial oxygen demand. Metabolic effects include hyperglycemia from hepatic glycogenolysis and hypokalemia from beta-2-mediated intracellular potassium shift. Notably, epinephrine increases lactate levels through aerobic glycolysis, which should not be confused with lactate elevation from tissue hypoperfusion.

### Clinical Use

In cardiac arrest, epinephrine is given as 1 mg IV every 3-5 minutes per ACLS protocols. For anaphylaxis, the dose is 0.3-0.5 mg intramuscularly, or 10-100 mcg IV in severe cases. It is also used for refractory hypotension and low cardiac output states as an infusion at 0.01-0.2 mcg/kg/min. Clinicians must recognize that epinephrine-induced lactate elevation does not indicate worsening tissue perfusion.

## Vasopressin (Arginine Vasopressin, ADH)

### Mechanism

Vasopressin acts on V1 receptors on vascular smooth muscle to cause vasoconstriction and on V2 receptors in the renal collecting duct to promote water reabsorption. Its vasoconstrictor effect does not rely on adrenergic pathways.

### Hemodynamic Effects

Vasopressin increases SVR without direct cardiac stimulation. It may slightly decrease heart rate and cardiac output. At low doses, pulmonary vasoconstriction is minimal. It is particularly effective in catecholamine-resistant vasodilatory shock because endogenous vasopressin stores become depleted during prolonged shock states.

### Clinical Use

Vasopressin serves as an adjunct to norepinephrine in septic shock. The VASST trial showed no overall mortality benefit but suggested a possible advantage in the subgroup with less severe shock. It is also used for post-cardiopulmonary bypass vasoplegia and hepatorenal syndrome. Unlike catecholamines, vasopressin is administered as a fixed-dose infusion at 0.01-0.04 units/min and is not titrated. At higher doses, it can cause splanchnic and digital ischemia.

<image>Side-by-side hemodynamic profile comparison of five vasopressors (phenylephrine, norepinephrine, epinephrine, vasopressin, and dopamine). For each agent, bar graphs show relative effects on heart rate, contractility, SVR, cardiac output, and MAP. Below each profile, the primary clinical indication and typical dose range are listed.</image>

## Dobutamine

### Mechanism

Dobutamine is a synthetic catecholamine that acts primarily as a beta-1 agonist with some beta-2 and weak alpha-1 activity. The net hemodynamic effect is increased contractility with mild vasodilation.

### Hemodynamic Effects

The primary effect of dobutamine is increased cardiac output. It mildly decreases SVR through beta-2-mediated vasodilation and increases heart rate, which can be problematic. By improving forward flow, it decreases PCWP. Dobutamine may cause hypotension if the patient is hypovolemic, because the combination of increased cardiac output and decreased SVR is poorly tolerated without adequate preload.

### Clinical Use

Dobutamine is used in low cardiac output states with adequate or elevated SVR, such as cardiogenic shock and post-CPB low output syndrome. It is often combined with norepinephrine when both cardiac output augmentation and blood pressure support are needed. The infusion rate ranges from 2-20 mcg/kg/min. Tachyphylaxis develops with prolonged use beyond 72 hours.

## Milrinone

### Mechanism

Milrinone is a phosphodiesterase-3 (PDE3) inhibitor, classified as an "inodilator." By inhibiting PDE3, it increases intracellular cAMP through a mechanism independent of beta-receptors. This independence means milrinone works even in patients on beta-blocker therapy or with beta-receptor downregulation from chronic heart failure.

### Hemodynamic Effects

Milrinone increases contractility (inotropy) and decreases both SVR and PVR (vasodilation). It also improves diastolic relaxation (lusitropy). Heart rate increases mildly. The vasodilatory effect can cause significant hypotension, particularly if volume status is not optimized.

### Clinical Use

Milrinone is particularly valuable in right heart failure because it reduces pulmonary vascular resistance, and in post-CPB low cardiac output, especially in patients on chronic beta-blockers. It is also used for decompensated heart failure with elevated afterload. The loading dose is 50 mcg/kg over 10-15 minutes, though this is often omitted to avoid hypotension. The infusion rate is 0.25-0.75 mcg/kg/min. Milrinone is renally cleared, requiring dose reduction in renal failure. Its longer half-life of approximately 2-3 hours means it cannot be rapidly titrated like dobutamine.

## Dopamine

### Mechanism -- Dose-Dependent

Dopamine has a dose-dependent receptor profile. At low doses (1-3 mcg/kg/min), D1 receptor activation causes renal vasodilation, though no clinical benefit has been proven. At moderate doses (3-10 mcg/kg/min), beta-1 effects predominate with increased inotropy and chronotropy. At high doses (above 10 mcg/kg/min), alpha-1 effects produce vasoconstriction.

### Clinical Concerns

Dopamine causes more arrhythmias than norepinephrine, as demonstrated in the SOAP II trial. The overlap between receptor effects at different doses makes titration imprecise. It is no longer first-line for most shock states, though some centers still use it for symptomatic bradycardia as an alternative to atropine or pacing.

### Vasoactive Agent Receptor Profile and Hemodynamic Effects Summary

| Agent | Alpha-1 | Beta-1 | Beta-2 | Mechanism | Primary Hemodynamic Effect | Typical Dose Range |
|---|---|---|---|---|---|---|
| Phenylephrine | +++ | 0 | 0 | Pure alpha agonist | Increases SVR; reflex bradycardia | 50–200 mcg bolus; 0.1–0.5 mcg/kg/min |
| Norepinephrine | +++ | ++ | 0/+ | Alpha + moderate beta-1 | Increases SVR and MAP; mild inotropy | 0.02–0.5 mcg/kg/min |
| Epinephrine | +++ | +++ | ++ | Dose-dependent alpha/beta | Increases HR, contractility, SVR (high dose) | 0.01–0.2 mcg/kg/min |
| Vasopressin | 0 | 0 | 0 | V1 receptor (non-adrenergic) | Increases SVR without cardiac stimulation | 0.01–0.04 units/min (fixed) |
| Dobutamine | +/0 | +++ | ++ | Synthetic catecholamine | Increases CO; mild vasodilation | 2–20 mcg/kg/min |
| Milrinone | 0 | 0 | 0 | PDE3 inhibitor (inodilator) | Increases CO; decreases SVR and PVR | 0.25–0.75 mcg/kg/min |
| Dopamine | + to +++ | + to +++ | + | Dose-dependent D1/beta/alpha | Variable: renal vasodilation to vasoconstriction | 1–20 mcg/kg/min |

## Evidence-Based Vasopressor Selection

### Septic Shock

The Surviving Sepsis Campaign guidelines recommend **norepinephrine** as first-line, with **vasopressin** added at 0.03 units/min as second-line to reduce norepinephrine requirements, and **epinephrine** as third-line. Stress-dose hydrocortisone should be considered in refractory cases.

### Cardiogenic Shock

For low cardiac output with hypotension, the combination of norepinephrine with dobutamine, or epinephrine alone, is recommended. For low cardiac output with normal or high blood pressure, dobutamine or milrinone alone may suffice. For right ventricular failure, milrinone (for PVR reduction) combined with norepinephrine (for systemic pressure support) is the preferred approach.

### Post-CPB Vasoplegia

Norepinephrine is first-line, with vasopressin as an adjunct. In refractory cases, methylene blue at 1-2 mg/kg may be effective through inhibition of nitric oxide synthase and guanylate cyclase.

### Anaphylaxis

**Epinephrine** is the drug of choice, providing alpha-mediated vasoconstriction, beta-1 inotropy, and beta-2 bronchodilation. Vasopressin serves as an adjunct in refractory anaphylaxis.

<image>Clinical decision algorithm for vasopressor selection in the operating room. The flowchart begins with the type of shock (distributive, cardiogenic, obstructive) and branches into specific etiologies (sepsis, anaphylaxis, neurogenic, post-CPB vasoplegia, RV failure, LV failure). Each endpoint shows the recommended first-line and second-line vasopressor/inotrope with dosing ranges.</image>

## Clinical Pearls

Phenylephrine boluses are convenient but can decrease cardiac output in patients with impaired systolic function; norepinephrine is often a better choice in these patients. An epinephrine-driven lactate elevation does not indicate worsening perfusion and should be distinguished from true tissue hypoxia using ScvO2 and clinical assessment. Milrinone is the preferred inotrope in right heart failure because it reduces PVR, but the resulting systemic vasodilation often requires a concomitant vasopressor. Vasopressin is not titrated like catecholamines; it should be used at a fixed low dose as an adjunct rather than as a primary vasopressor. Adequate volume resuscitation must always be ensured before starting vasopressors, as vasoconstrictors in the setting of hypovolemia worsen tissue perfusion. Dopamine has largely fallen out of favor due to its arrhythmogenic profile demonstrated in the SOAP II trial.

## References

- De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock (SOAP II). *New England Journal of Medicine*. 2010;362(9):779-789.
- Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock (VASST). *New England Journal of Medicine*. 2008;358(9):877-887.
- Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Medicine*. 2021;47(11):1181-1247.
- Overgaard CB, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. *Circulation*. 2008;118(10):1047-1056.
- Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2015;20(3):249-260.